Cocrystal Pharma, Inc. (NASDAQ:COCP) Sees Large Increase in Short Interest

Cocrystal Pharma, Inc. (NASDAQ:COCP) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 6,200 shares, a growth of 313.3% from the March 31st total of 1,500 shares. Based on an average daily trading volume, of 21,700 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.1% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Cocrystal Pharma in a research report on Wednesday, January 22nd.

Cocrystal Pharma Stock Performance

Shares of COCP stock opened at $1.65 on Tuesday. Cocrystal Pharma has a fifty-two week low of $1.12 and a fifty-two week high of $3.26. The stock’s fifty day moving average price is $1.52 and its two-hundred day moving average price is $1.87. The company has a market cap of $16.78 million, a PE ratio of -0.89 and a beta of 2.21.

Cocrystal Pharma (NASDAQ:COCP) last issued its earnings results on Thursday, March 27th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.23. On average, equities analysts predict that Cocrystal Pharma will post -1.85 EPS for the current fiscal year.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.